Your Top 100 most-cited badge
A badge for your website, a sentence for your CV, and a permanent page where anyone can check the rank.
The article
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
Ross Andrew Soo, Ji‐Youn Han, Urania G. Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal and 24 more
- Rank
- 61 of 3,031
- Percentile
- top 2.1%
- Where
- Annals of Oncology, 2021
- Citations
- 108
From the 2021 list, OpenAlex counts as of 2026-10-29.
Prefer not to be listed? The same link lets you withhold your name on every list; the article stays, your name does not. Questions: team@avidnote.com.